<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26036916</PMID><DateCompleted><Year>2016</Year><Month>06</Month><Day>20</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2164-554X</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>Human vaccines &amp; immunotherapeutics</Title><ISOAbbreviation>Hum Vaccin Immunother</ISOAbbreviation></Journal><ArticleTitle>Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice.</ArticleTitle><Pagination><StartPage>2406</StartPage><EndPage>2413</EndPage><MedlinePgn>2406-13</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/21645515.2015.1053675</ELocationID><Abstract><AbstractText>Enterovirus 71(EV71) has caused severe epidemics of hand, foot and mouth disease (HFMD) in the Asia Pacific in recent years, particularly in infants and pre-school children. It has become a serious public health threat, as currently there are no approved vaccines or antiviral drugs for EV71 infection. Many EV71 vaccines have been under development worldwide, however the main focus is inactivated EV71 vaccines. For example, the inactivated EV71 vaccine has recently finished phase III clinical trial in Mainland China. There have been very few studies on EV71 virus like particles (VLPs). In this study, the immunogenicity and protective potency of the EV71 VLPs produced in insect cells were evaluated in mice with different dosages. Our results showed that EV71 VLPs could elicit high titers of neutralizing antibodies (NTAbs) in a dose-dependent manner and NTAbs were sustained after the second injection with an average GMT (geometric mean titer) level from 19 to 2960 in immunized mice. Survival rates were 100%, 100%, 85%, and 40% after challenge with 15 LD50 (median lethal dose) of EV71 in these newborn mice, respectively. ED50 (50% effective dose) of VLPs was 0.20 &#x3bc;g/dose in newborn mice, while NTAb titer under this dosage was about 50. Passive protection was determined with 2 methods and demonstrated that the survival rates were positively correlated with NTAb titers, which at 24 and 54 induced 50% survival rates in experimental animals. The ED50 of VLP vaccines and the passive NTAb titers were also analyzed. The maternal NTAb titer was similar as the passive NTAb titer in the mouse model challenged with our lethal mouse EV71 strain. Hence, our work has provided preliminary data on the protection potency of VLPs as a vaccine candidate and would facilitate future VLP vaccine development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Shiyang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>a School of Life Sciences; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b National Engineering Laboratory for AIDS Vaccine; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>c National Institutes for Food and Drug Control ; Beijing , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>c National Institutes for Food and Drug Control ; Beijing , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shao</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>a School of Life Sciences; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b National Engineering Laboratory for AIDS Vaccine; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Liping</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>a School of Life Sciences; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b National Engineering Laboratory for AIDS Vaccine; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dawei</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>d Changchun BCHT Biotechnology Co. ; Changchun , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yiping</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>c National Institutes for Food and Drug Control ; Beijing , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yao</LastName><ForeName>Xin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>c National Institutes for Food and Drug Control ; Beijing , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>c National Institutes for Food and Drug Control ; Beijing , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>d Changchun BCHT Biotechnology Co. ; Changchun , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Dandan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>a School of Life Sciences; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b National Engineering Laboratory for AIDS Vaccine; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Youlei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>d Changchun BCHT Biotechnology Co. ; Changchun , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Jingcai</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>a School of Life Sciences; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b National Engineering Laboratory for AIDS Vaccine; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>a School of Life Sciences; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b National Engineering Laboratory for AIDS Vaccine; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>e Key Laboratory for Molecular Enzymology &amp; Engineering; The Ministry of Education; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Chunlai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>a School of Life Sciences; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b National Engineering Laboratory for AIDS Vaccine; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>e Key Laboratory for Molecular Enzymology &amp; Engineering; The Ministry of Education; Jilin University ; Changchun , PR China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>c National Institutes for Food and Drug Control ; Beijing , PR China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Hum Vaccin Immunother</MedlineTA><NlmUniqueID>101572652</NlmUniqueID><ISSNLinking>2164-5515</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014614">Vaccines, Synthetic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000831" MajorTopicYN="N">Animals, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007313" MajorTopicYN="N">Insecta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008813" MajorTopicYN="N">Mice, Inbred ICR</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014614" MajorTopicYN="N">Vaccines, Synthetic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="N">Vaccines, Virus-Like Particle</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ED50 (50% effective dose)</Keyword><Keyword MajorTopicYN="N">HFMD</Keyword><Keyword MajorTopicYN="N">VLP vaccine</Keyword><Keyword MajorTopicYN="N">enterovirus 71</Keyword><Keyword MajorTopicYN="N">hand foot and mouth disease</Keyword><Keyword MajorTopicYN="N">immunogenicity</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2016</Year><Month>6</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26036916</ArticleId><ArticleId IdType="pmc">PMC4635907</ArticleId><ArticleId IdType="doi">10.1080/21645515.2015.1053675</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mirand A, Henquell C, Archimbaud C, Ughetto S, Antona D, Bailly JL, Peigue-Lafeuille H. Outbreak of hand, foot and mouth disease/herpangina associated with coxsackievirus A6 and A10 infections in 2010, France: a large citywide, prospective observational study. Clini Microbiol Infect 2012; 18:E110-8; PMID:22404077; http://dx.doi.org/10.1111/j.1469-0691.2012.03789.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1469-0691.2012.03789.x</ArticleId><ArticleId IdType="pubmed">22404077</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu QB, Zhang XA, Wo Y, Xu HM, Li XJ, Wang XJ, Ding SJ, Chen XD, He C, Liu LJ, et&#xa0;al.. Circulation of Coxsackievirus A10 and A6 in hand-foot-mouth disease in China, 2009&#x2013;2011. PLoS One 2012; 7:e52073; PMID:23272213; http://dx.doi.org/10.1371/journal.pone.0052073</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052073</ArticleId><ArticleId IdType="pmc">PMC3525556</ArticleId><ArticleId IdType="pubmed">23272213</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon T, Lewthwaite P, Perera D, Cardosa MJ, McMinn P, Ooi MH. Virology, epidemiology, pathogenesis, and control of enterovirus 71. Lancet Infect Dis 2010; 10:778-90; PMID:20961813; http://dx.doi.org/10.1016/S1473-3099(10)70194-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(10)70194-8</ArticleId><ArticleId IdType="pubmed">20961813</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Yao X, Bian L, Wu X, Xu M, Liang Z. Coxsackievirus A16: epidemiology, diagnosis, and vaccine. Hum Vaccines Immunother 2014; 10:360-7; PMID:24231751; http://dx.doi.org/10.1080/21645515.2015.1008870</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1008870</ArticleId><ArticleId IdType="pmc">PMC4185891</ArticleId><ArticleId IdType="pubmed">24231751</ArticleId></ArticleIdList></Reference><Reference><Citation>Yi L, Lu J, Kung HF, He ML. The virology and developments toward control of human enterovirus 71. Critical Rev Microbiol 2011; 37:313-27; PMID:21651436; http://dx.doi.org/10.3109/1040841X.2011.580723</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/1040841X.2011.580723</ArticleId><ArticleId IdType="pubmed">21651436</ArticleId></ArticleIdList></Reference><Reference><Citation>McMinn PC. An overview of the evolution of enterovirus 71 and its clinical and public health significance. Fems Microbiol Rev 2002; 26:91-107; PMID:12007645; http://dx.doi.org/10.1111/j.1574-6976.2002.tb00601.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1574-6976.2002.tb00601.x</ArticleId><ArticleId IdType="pubmed">12007645</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwai M, Masaki A, Hasegawa S, Obara M, Horimoto E, Nakamura K, Tanaka Y, Endo K, Tanaka K, Ueda J, et&#xa0;al.. Genetic changes of coxsackievirus A16 and enterovirus 71 isolated from hand, foot, and mouth disease patients in Toyama, Japan between 1981 and 2007. Japan J Infect Dis 2009; 62:254-9; PMID:19628900</Citation><ArticleIdList><ArticleId IdType="pubmed">19628900</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang LY, Lin TY, Huang YC, Tsao KC, Shih SR, Kuo ML, Ning HC, Chung PW, Kang CM. Comparison of enterovirus 71 and coxsackie-virus A16 clinical illnesses during the Taiwan enterovirus epidemic, 1998. Pediatr Infect Dis J 1999; 18:1092-6; PMID:10608631; http://dx.doi.org/10.1097/00006454-199912000-00013</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006454-199912000-00013</ArticleId><ArticleId IdType="pubmed">10608631</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 1974; 129:304-9; PMID:4361245; http://dx.doi.org/10.1093/infdis/129.3.304</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/129.3.304</ArticleId><ArticleId IdType="pubmed">4361245</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimoto T, Chikahira M, Yoshida S, Ebira H, Hasegawa A, Totsuka A, Nishio O. Outbreak of central nervous system disease associated with hand, foot, and mouth disease in Japan during the summer of 2000: detection and molecular epidemiology of enterovirus 71. Microbiol Immunol 2002; 46:621-7; PMID:12437029; http://dx.doi.org/10.1111/j.1348-0421.2002.tb02743.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1348-0421.2002.tb02743.x</ArticleId><ArticleId IdType="pubmed">12437029</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho M, Chen ER, Hsu KH, Twu SJ, Chen KT, Tsai SF, Wang JR, Shih SR. An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group. N Engl J Med 1999; 341:929-35; PMID:10498487; http://dx.doi.org/10.1056/NEJM199909233411301</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199909233411301</ArticleId><ArticleId IdType="pubmed">10498487</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendig JW, Fleming DM. Epidemiological, virological, and clinical features of an epidemic of hand, foot, and mouth disease in England and Wales. Commun Dis Rep CDR Rev 1996; 6:R81-6; PMID:8664928</Citation><ArticleIdList><ArticleId IdType="pubmed">8664928</ArticleId></ArticleIdList></Reference><Reference><Citation>NNDRS 

2014 http://wwwnhfpcgovcn/zhuzhan/yqxx/listshtml</Citation></Reference><Reference><Citation>Zhu FC, Meng FY, Li JX, Li XL, Mao QY, Tao H, Zhang YT, Yao X, Chu K, Chen QH, et&#xa0;al.. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2013; 381:2024-32; PMID:23726161; http://dx.doi.org/10.1016/S0140-6736(13)61049-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61049-1</ArticleId><ArticleId IdType="pubmed">23726161</ArticleId></ArticleIdList></Reference><Reference><Citation>Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, et&#xa0;al.. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369:2161-70; PMID:17602732; http://dx.doi.org/10.1016/S0140-6736(07)60946-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)60946-5</ArticleId><ArticleId IdType="pubmed">17602732</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Ma Y, Wang H, Liu Q. Quantitative evaluation of the effect of the hepatitis B vaccine based on the HBsAg- and anti-HBs-positive rates in the Chinese population over the last 33&#xa0;years. Vaccine 2012; 30:3483-7; PMID:22433962; http://dx.doi.org/10.1016/j.vaccine.2012.02.053</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2012.02.053</ArticleId><ArticleId IdType="pubmed">22433962</ArticleId></ArticleIdList></Reference><Reference><Citation>www.clinicaltrials.gov (Identifier NCT01897701)</Citation></Reference><Reference><Citation>Sun S, Jiang L, Liang Z, Mao Q, Su W, Zhang H, Li X, Jin J, Xu L, Zhao D, et&#xa0;al.. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice. Hum Vaccines Immunother 2014; 10:2885-95; PMID:25483672; http://dx.doi.org/10.4161/hv.29823</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.29823</ArticleId><ArticleId IdType="pmc">PMC5443096</ArticleId><ArticleId IdType="pubmed">25483672</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Dong C, Li X, Gao Q, Guo Z, Yao X, Wang Y, Gao F, Li F, Xu M, et&#xa0;al.. Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice. PLoS One 2012; 7:e46043; PMID:23029378; http://dx.doi.org/10.1371/journal.pone.0046043</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0046043</ArticleId><ArticleId IdType="pmc">PMC3460965</ArticleId><ArticleId IdType="pubmed">23029378</ArticleId></ArticleIdList></Reference><Reference><Citation>Bek EJ, Hussain KM, Phuektes P, Kok CC, Gao Q, Cai F, Gao Z, McMinn PC. Formalin-inactivated vaccine provokes cross-protective immunity in a mouse model of human enterovirus 71 infection. Vaccine 2011; 29:4829-38; PMID:21550375; http://dx.doi.org/10.1016/j.vaccine.2011.04.070</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.04.070</ArticleId><ArticleId IdType="pubmed">21550375</ArticleId></ArticleIdList></Reference><Reference><Citation>Giersing BK, Dubovsky F, Saul A, Denamur F, Minor P, Meade B. Potency assay design for adjuvanted recombinant proteins as malaria vaccines. Vaccine 2006; 24:4264-70; PMID:16767804; http://dx.doi.org/10.1016/j.vaccine.2006.01.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2006.01.005</ArticleId><ArticleId IdType="pubmed">16767804</ArticleId></ArticleIdList></Reference><Reference><Citation>DJ. F Probit analysis. 3rd ed. London: Cambrige university press; 1971</Citation></Reference><Reference><Citation>DJ. F Statistical methodology in biological assay. 3rd ed. London: Charles Griffin and Company; 1978</Citation></Reference><Reference><Citation>Sokol RR RF Biometry: the principles and practice of statistics in biological research. 3rd ed. Newyork: W.H. Freeman and Company; 1995</Citation></Reference><Reference><Citation>Gaines RE, Tydeman MS. Iterative weighted regression analysis of logit responses: a computer program for analysis of bioassays and immunoassays. Comput Programs Biomed 1982; 15:13-21; PMID:7128120; http://dx.doi.org/10.1016/0010-468X(82)90052-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0010-468X(82)90052-6</ArticleId><ArticleId IdType="pubmed">7128120</ArticleId></ArticleIdList></Reference><Reference><Citation>Commission EP. Statistical analysis of results of bioligical assays and test. European Pharmacopoeia, 5th ed. Strasburg: Council of Europe, 475-504</Citation></Reference><Reference><Citation>2010. P. Pharmacopoeia of the People's Republic of China (2010 Edition):</Citation></Reference><Reference><Citation>Zhu F, Xu W, Xia J, Liang Z, Liu Y, Zhang X, Tan X, Wang L, Mao Q, Wu J, et&#xa0;al.. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med 2014; 370:818-28; PMID:24571754; http://dx.doi.org/10.1056/NEJMoa1304923</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1304923</ArticleId><ArticleId IdType="pubmed">24571754</ArticleId></ArticleIdList></Reference><Reference><Citation>Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, et&#xa0;al.. An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 2014; 370:829-37; PMID:24571755; http://dx.doi.org/10.1056/NEJMoa1303224</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1303224</ArticleId><ArticleId IdType="pubmed">24571755</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng A, Fung CP, Liu CC, Lin YT, Tsai HY, Chang SC, Chou AH, Chang JY, Jiang RH, Hsieh YC, et&#xa0;al.. A Phase I, randomized, open-label study to evaluate the safety and immunogenicity of an enterovirus 71 vaccine. Vaccine 2013; 31:2471-6; PMID:23541623; http://dx.doi.org/10.1016/j.vaccine.2013.03.015</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.03.015</ArticleId><ArticleId IdType="pubmed">23541623</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, Han JF, Qin CF, Chen R. Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 2013; 31:3281-7; PMID:23726823; http://dx.doi.org/10.1016/j.vaccine.2013.05.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2013.05.019</ArticleId><ArticleId IdType="pubmed">23726823</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin YL, Yu CI, Hu YC, Tsai TJ, Kuo YC, Chi WK, Lin AN, Chiang BL. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 2012; 30:1305-12; PMID:22214888; http://dx.doi.org/10.1016/j.vaccine.2011.12.081</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.12.081</ArticleId><ArticleId IdType="pubmed">22214888</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung YC, Ho MS, Wu JC, Chen WJ, Huang JH, Chou ST, Hu YC. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008; 26:1855-62; PMID:18329759; http://dx.doi.org/10.1016/j.vaccine.2008.01.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2008.01.058</ArticleId><ArticleId IdType="pubmed">18329759</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Wang J. EV71 vaccine, an invaluable gift for children. Clin Translat Immunol 2014; 3:e28; PMID:25505956; http://dx.doi.org/10.1038/cti.2014.24</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cti.2014.24</ArticleId><ArticleId IdType="pmc">PMC4237031</ArticleId><ArticleId IdType="pubmed">25505956</ArticleId></ArticleIdList></Reference><Reference><Citation>de Moura WC, de Araujo HP, Cabello PH, Romijn PC, Leite JP. Potency evaluation of rabies vaccine for human use: the impact of the reduction in the number of animals per dilution. J Virol Methods 2009; 158:84-92; PMID:19428574; http://dx.doi.org/10.1016/j.jviromet.2009.01.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2009.01.017</ArticleId><ArticleId IdType="pubmed">19428574</ArticleId></ArticleIdList></Reference><Reference><Citation>Leslie DE, Nicholson S, Dimitrakakis M, Johnston N, Gust ID. Humoral immune responses in mice using gamma inulin preparations as adjuvants for hepatitis B vaccines. Immunol Cell Biol 1990; 68 (Pt 2):107-12; PMID:1696560; http://dx.doi.org/10.1038/icb.1990.15</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/icb.1990.15</ArticleId><ArticleId IdType="pubmed">1696560</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SW, Zhang J, Li YM, Ou SH, Huang GY, He ZQ, Ge SX, Xian YL, Pang SQ, Ng MH, et&#xa0;al.. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates. Vaccine 2005; 23:2893-901; PMID:15780738; http://dx.doi.org/10.1016/j.vaccine.2004.11.064</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2004.11.064</ArticleId><ArticleId IdType="pubmed">15780738</ArticleId></ArticleIdList></Reference><Reference><Citation>Li SW, Zhao Q, Wu T, Chen S, Zhang J, Xia NS. The development of a recombinant hepatitis E vaccine HEV 239. Hum Vaccines Immunother 2015:11(4):908-14; PMID:25714510</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4514148</ArticleId><ArticleId IdType="pubmed">25714510</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang Z, Mao Q, Gao Q, Li X, Dong C, Yu X, Yao X, Li F, Yin W, Li Q, et&#xa0;al.. Establishing China's national standards of antigen content and neutralizing antibody responses for evaluation of enterovirus 71 (EV71) vaccines. Vaccine 2011; 29:9668-74; PMID:22015395; http://dx.doi.org/10.1016/j.vaccine.2011.10.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2011.10.018</ArticleId><ArticleId IdType="pubmed">22015395</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu CN, Lin YC, Fann C, Liao NS, Shih SR, Ho MS. Protection against lethal enterovirus 71 infection in newborn mice by passive immunization with subunit VP1 vaccines and inactivated virus. Vaccine 2001; 20:895-904; PMID:11738755; http://dx.doi.org/10.1016/S0264-410X(01)00385-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0264-410X(01)00385-1</ArticleId><ArticleId IdType="pubmed">11738755</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiu CH, Chu C, He CC, Lin TY. Protection of neonatal mice from lethal enterovirus 71 infection by maternal immunization with attenuated Salmonella enterica serovar Typhimurium expressing VP1 of enterovirus 71. Microb infect 2006; 8:1671-8; PMID:16815726; http://dx.doi.org/10.1016/j.micinf.2006.01.021</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2006.01.021</ArticleId><ArticleId IdType="pubmed">16815726</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang BY, Wang XP, Tang WJ, Wang WL, Ruan L. The 50% effective dose (ED50a) of seasonal spilt influenza vaccine in mice. Chin J Exp Clin Virol 2011; 25:92-5; PMID:21863626</Citation><ArticleIdList><ArticleId IdType="pubmed">21863626</ArticleId></ArticleIdList></Reference><Reference><Citation>Einstein MH, Takacs P, Chatterjee A, Sperling RS, Chakhtoura N, Blatter MM, Lalezari J, David MP, Lin L, Struyf F, et&#xa0;al.. Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18&#x2013;45&#xa0;years: End-of-study analysis of a Phase III randomized trial. Hum Vaccines Immunother 2014; 10:3435-45; PMID:25483701; http://dx.doi.org/10.4161/hv.36121</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.36121</ArticleId><ArticleId IdType="pmc">PMC4514070</ArticleId><ArticleId IdType="pubmed">25483701</ArticleId></ArticleIdList></Reference><Reference><Citation>Einstein MH, Levin MJ, Chatterjee A, Chakhtoura N, Takacs P, Catteau G, Dessy FJ, Moris P, Lin L, Struyf F, et&#xa0;al.. Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women aged 18&#x2013;45&#xa0;years: Follow-up through Month&#xa0;48 in a Phase III randomized study. Hum Vaccines Immunother 2014; 10:3455-65; PMID:25483700; http://dx.doi.org/10.4161/hv.36117</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/hv.36117</ArticleId><ArticleId IdType="pmc">PMC4514093</ArticleId><ArticleId IdType="pubmed">25483700</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Fan P, Jin J, Su W, An D, Xu L, Sun S, Zhang Y, Meng X, Gao F, et&#xa0;al.. Establishment of cell lines with increased susceptibility to EV71/CA16 by stable overexpression of SCARB2. Virol J 2013; 10:250; PMID:23919614; http://dx.doi.org/10.1186/1743-422X-10-250</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1743-422X-10-250</ArticleId><ArticleId IdType="pmc">PMC3765843</ArticleId><ArticleId IdType="pubmed">23919614</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu X, Mao Q, Yao X, Chen P, Chen X, Shao J, Sun S, Zhang Y, Meng X, Gao F, et&#xa0;al.. Development and evaluation of a pseudovirus-luciferase assay for rapid and quantitative detection of neutralizing antibodies against enterovirus 71. PLoS One 2013; 8:e64116; PMID:23755115; http://dx.doi.org/10.1371/journal.pone.0064116</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0064116</ArticleId><ArticleId IdType="pmc">PMC3673970</ArticleId><ArticleId IdType="pubmed">23755115</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J, Xu L, Guo S, Sun S, Zhang S, Zhu C, Kong W, Jiang C. Safe and Objective Assay of Enterovirus 71 Neutraliziong Antibodies Via Pseudovirus Chem Res Chinese Universities 2012; 28:91-95</Citation></Reference><Reference><Citation>Zhang H, An D, Liu W, Mao Q, Jin J, Xu L, Sun S, Jiang L, Li X, Shao J, et&#xa0;al.. Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay. PLoS One 2014; 9:e100545; PMID:24964084; http://dx.doi.org/10.1371/journal.pone.0100545</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0100545</ArticleId><ArticleId IdType="pmc">PMC4070950</ArticleId><ArticleId IdType="pubmed">24964084</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao Q, Wang Y, Gao R, Shao J, Yao X, Lang S, Wang C, Mao P, Liang Z, Wang J. A neonatal mouse model of coxsackievirus A16 for vaccine evaluation. J Virol 2012; 86:11967-76; PMID:22951825; http://dx.doi.org/10.1128/JVI.00902-12</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00902-12</ArticleId><ArticleId IdType="pmc">PMC3486452</ArticleId><ArticleId IdType="pubmed">22951825</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>